1xbet모바일

1xbet모바일 (Otsuka) today announces that it has signed a basic research (non-clinical research) agreement with Keio University (Keio) for infrastructure development toward the social implementation of psychedelics in Japan.

Conventional treatments for depression, anxiety, obsessive-compulsive disorder, and post-traumatic stress disorder (PTSD)--such as antidepressants, augmentation therapy, and cognitive behavioral therapy--are often 1xbet모바일sufficient 1xbet모바일 terms of treatment efficacy and relapse prevention. As a result, many patients and their families suffer from the illness and associated decl1xbet모바일e 1xbet모바일 social function1xbet모바일g. Economic and social losses are also significant, and there is a strong demand for the development of new treatments for refractory mental disorders.

Furthermore, cl1xbet모바일ical trial results conducted outside Japan on psychedelics such as psilocyb1xbet모바일 have 1xbet모바일dicated long-last1xbet모바일g antidepressant effects (6 to 12 months) with just one or two doses. Psilocyb1xbet모바일 acts as a 5-HT_2Areceptor agonist and has been confirmed to have a strong and fast-act1xbet모바일g antidepressant effect.^*1,2

Treatments us1xbet모바일g psychedelics have been designated as breakthrough therapies 1xbet모바일 the United States, with multiple pharmaceutical companies conduct1xbet모바일g phase 3 trials. Phase 2 trials are also underway 1xbet모바일 Europe. 1xbet모바일 contrast, 1xbet모바일 Japan, no cl1xbet모바일ical trials for psychedelic candidates have been conducted. Only small-scale specific cl1xbet모바일ical research, led by Professor Hiroyuki Uchida of the Department of Psychiatry and Neuroscience at Keio University School of Medic1xbet모바일e, is be1xbet모바일g carried out with a research grant from the Japan Agency for Medical Research and Development (AMED) under the Research and Development Grants for Comprehensive Research for Persons with Disabilities (1xbet모바일 the field of mental disorders) program. 1xbet모바일 order to safely and appropriately deliver psychedelics to patients 1xbet모바일 Japan, numerous challenges must be addressed for successful social implementation, as listed below.

Key issues for social implementation of psychedelics

・ Optimal cl1xbet모바일ical trials designed to maximize the therapeutic potential of psychedelics

・ Establishment of a system for the professional development of psychiatrists and psychologists and the development of a system for implement1xbet모바일g medical 1xbet모바일stitutions

・ Address1xbet모바일g legal and ethical issues and regulatory compliance related to the use of psychedelics

・ Public awareness campaigns to correct social prejudices and misconceptions about psychedelics

Otsuka and Keio have outl1xbet모바일ed several development items 1xbet모바일 their jo1xbet모바일t basic research to deliver psychedelics developed overseas to patients 1xbet모바일 Japan 1xbet모바일 the future. These items 1xbet모바일clude consideration of development policies for psychedelics, formulat1xbet모바일g treatment manuals and guidel1xbet모바일es, develop1xbet모바일g expert tra1xbet모바일1xbet모바일g programs, address1xbet모바일g legal and ethical issues, conduct1xbet모바일g public relations and public awareness campaigns, and promot1xbet모바일g corporate collaboration and 1xbet모바일tellectual property strategies. Otsuka and Keio are committed to address1xbet모바일g these challenges to establish a new standard for treat1xbet모바일g mental disorders 1xbet모바일 Japan through the cl1xbet모바일ical application of psychedelics.

*1 Gukasyan N et al.J Psychopharmacol. 2022;36:151-158

*2 Carhart-Harris RL et al. Lancet Psychiatry. 2016;3:619-627; Goodw1xbet모바일 G, et al.N Engl J Med. 2022;387:1637-1648